Latest news for Aeris Resources (OTC:ARSRF) Stock

Aeris Resources Ltd is a mineral exploration and production company. It engages in mineral production and sale of copper, gold, and silver and the exploration of copper. Business operating segments are organized into 6 divisions being: Tritton Copper Operations (Tritton) in New South Wales; Cracow Gold Operations (Cracow) in Queensland; North West Copper Operations (North West) in Queensland, Jaguar Zinc and Copper Operations (Jaguar) in Western Australia; Stockman Copper and Zinc Project (Stockman) in Victoria; and Others, representing corporate activities. Substantial revenue is generated from Tritton Copper Operation.

AERIS RESOURCES LTD by Aeris Resources Ltd.

Aeris Resources Ltd

WIIM

PLXS

Plexus shares are trading higher following upbeat Q4 guidance.

News

Politics

General

Trump Leads Harris 48%-46% Among Registered Voters, NYT/Sienna College Poll Finds; Margin Of Error Is 3.3 Points

COSM

Cosmos Health's Subsidiary Decahedron Successfully Submits Tender To Supply NHS Scotland With C-Scrub Wash Chlorhexidine 4%

U.S. Justice Dept Files Lawsuit Against National General Holdings And Subsidiaries For Misleadingly Insuring Hundreds Of Thousands Of Borrowers' Vehicles

Financial giants have made a conspicuous bearish move on Linde. Our analysis of options history for Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) revealed 10 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $65,580, and 8 were calls, valued at $466,188.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $455.0 for Linde over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Linde's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Linde's substantial trades, within a strike price spectrum from $400.0 to $455.0 over the preceding 30 days.
<h3>Linde Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721933229_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.4</td>
<td>$26.7</td>
<td>$26.7</td>
<td>$450.00</td>
<td>$95.9K</td>
<td>2.6K</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>LIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$26.6</td>
<td>$26.4</td>
<td>$26.5</td>
<td>$450.00</td>
<td>$74.2K</td>
<td>2.6K</td>
<td style="text-align: right;">165</td>
</tr>
<tr>
<td>LIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$26.8</td>
<td>$26.7</td>
<td>$26.58</td>
<td>$450.00</td>
<td>$69.2K</td>
<td>2.6K</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>LIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$85.1</td>
<td>$83.2</td>
<td>$83.8</td>
<td>$400.00</td>
<td>$58.7K</td>
<td>29</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>LIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$27.9</td>
<td>$26.7</td>
<td>$26.58</td>
<td>$450.00</td>
<td>$58.5K</td>
<td>2.6K</td>
<td style="text-align: right;">98</td>
</tr>
</tbody>
</table>

<h3>About Linde</h3>
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2023.
Having examined the options trading patterns of Linde, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Linde</h3>
<ul>
<li>With a volume of 773,982, the price of LIN is up 0.57% at $446.31. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What The Experts Say On Linde</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $477.5.
<ul>
<li>An analyst from UBS persists with their Neutral rating on Linde, maintaining a target price of $475. </li>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Linde, targeting a price of $480. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Linde options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Behind the Scenes of Linde's Latest Options Trends

High-rolling investors have positioned themselves bullish on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in RMD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for ResMed. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $85,680, and 7 calls, totaling $316,157.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $230.0 for ResMed, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ResMed's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ResMed's whale trades within a strike price range from $200.0 to $230.0 in the last 30 days. 
<h3>ResMed 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721933224_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$13.9</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$210.00</td>
<td>$93.6K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">71</td>
</tr>
<tr>
<td>RMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$200.00</td>
<td>$85.6K</td>
<td style="text-align: right;">299</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$8.3</td>
<td>$7.8</td>
<td>$8.3</td>
<td>$220.00</td>
<td>$76.3K</td>
<td style="text-align: right;">688</td>
<td style="text-align: right;">357</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$8.7</td>
<td>$8.2</td>
<td>$8.6</td>
<td>$220.00</td>
<td>$31.8K</td>
<td style="text-align: right;">688</td>
<td style="text-align: right;">395</td>
</tr>
<tr>
<td>RMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$7.8</td>
<td>$7.1</td>
<td>$7.8</td>
<td>$220.00</td>
<td>$31.2K</td>
<td style="text-align: right;">688</td>
<td style="text-align: right;">127</td>
</tr>
</tbody>
</table>

<h3>About ResMed</h3>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Following our analysis of the options activities associated with ResMed, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of ResMed</h3>
<ul>
<li>Trading volume stands at 402,637, with RMD's price down by 0.0%, positioned at $206.2.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Expert Opinions on ResMed</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $204.0.
<ul>
<li>Maintaining their stance, an analyst from RBC Capital continues to hold a Sector Perform rating for ResMed, targeting a price of $204. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ResMed options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of ResMed's Latest Options Trends

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories.
Looking at options history for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $96,943 and 6, calls, for a total amount of $244,146.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $105.0 to $130.0 for Abbott Laboratories over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Abbott Laboratories's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abbott Laboratories's whale trades within a strike price range from $105.0 to $130.0 in the last 30 days. 
<h3>Abbott Laboratories Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721933219_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$4.2</td>
<td>$4.05</td>
<td>$4.15</td>
<td>$105.00</td>
<td>$103.7K</td>
<td>8.3K</td>
<td style="text-align: right;">489</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.71</td>
<td>$2.66</td>
<td>$2.7</td>
<td>$107.00</td>
<td>$57.7K</td>
<td>108</td>
<td style="text-align: right;">621</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$23.2</td>
<td>$22.85</td>
<td>$23.05</td>
<td>$130.00</td>
<td>$39.1K</td>
<td>0</td>
<td style="text-align: right;">17</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$1.8</td>
<td>$1.64</td>
<td>$1.8</td>
<td>$106.00</td>
<td>$29.8K</td>
<td>1.6K</td>
<td style="text-align: right;">684</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.98</td>
<td>$2.54</td>
<td>$2.82</td>
<td>$115.00</td>
<td>$28.2K</td>
<td>1.8K</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Following our analysis of the options activities associated with Abbott Laboratories, we pivot to a closer look at the company's own performance.
<h3>Where Is Abbott Laboratories Standing Right Now?</h3>
<ul>
<li>With a volume of 3,572,917, the price of ABT is down -0.69% at $106.52. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Abbott Laboratories</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $120.0.
<ul>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Abbott Laboratories with a target price of $120. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Abbott Laboratories options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Abbott Laboratories's Latest Options Trends

United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) shares are trading higher by 1.6% to $46.77 during Thursday&#8217;s session, rebounding following earlier weakness. Shares are volatile following <a href="https://www.benzinga.com/news/earnings/24/07/39957077/southwest-airlines-q2-earnings-plummet-ceo-promises-transformational-changes">financial results</a> from American Airlines Group Inc and Southwest Airlines Co.
When major players in the industry like American and Southwest report disappointing results or lower guidance, it often leads to a negative outlook for the sector as a whole. Investors may fear that United Airlines could face similar issues.
Southwest&#8217;s report highlights that industry-wide domestic capacity growth outpaced demand. This is a critical factor that could affect United Airlines, suggesting they might also experience pressure on unit revenues.
Southwest also reported significant increases in operating expenses due to market-driven inflation in salaries, wages, benefits, and higher maintenance expenses. These cost pressures could be industry-wide and may similarly impact United Airlines&#8217; profitability.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39951461/markets-are-sounding-an-alarm-peter-schiff-warns-federal-reserve-should-cut-rates-b">Peter Schiff Warns Federal Reserve Should Cut Rates Before Recession Hits</a>

What's Going On With United Airlines (UAL) Stock?

JP Morgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) is reportedly gauging investor interest in a possible issuance of high-yield bonds by Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), aimed at managing the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39580104/cvs-rite-aid-walgreens-hit-hard-by-online-pharmacy-trend" rel="noreferrer noopener">drug-store chain&#8217;s recently downgraded near-term debt obligations.</a>
Preliminary discussions on pricing suggest a yield in the vicinity of 7.5%, <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-25/jpmorgan-sounds-out-investors-on-potential-walgreens-junk-bond?sref=TBDibEcD" rel="noreferrer noopener">reported</a> Bloomberg, citing people familiar with the discussions.
The specific size and duration of the deal have not been finalized. Walgreens currently holds a $1.16 billion note maturing on November 18, trading close to par, and a £300 million ($387 million) bond due in late 2025, as per Bloomberg data.
Should Walgreens proceed with a bond sale, it would mark their first issuance since being downgraded to junk status by both Moody&#8217;s Ratings and S&amp;P Global Ratings.
Also Read: &nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/03/37952625/rite-aid-forges-path-to-financial-recovery-with-major-settlement-report" rel="noreferrer noopener">Rite Aid Forges Path To Financial Recovery With Major Settlement: Report</a>
This move would entail significantly higher costs, with the highest coupon rate currently at 4.8% on a 2044 bond issued a decade ago.
In January, Walgreens nearly halved its dividend following a CEO change. Meanwhile,&nbsp;&nbsp;Rite Aid Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RADCQ#OTC">RADCQ</a>) is in bankruptcy, CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) faces retail challenges, and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)
<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38529328/walmart-to-shut-down-all-clinic-locations-amid-rising-costs-what-it-means-for-your-healthcare" rel="noreferrer noopener">scrapped plans for low-cost clinics due to cost and reimbursement issues.</a>
S&amp;P&#8217;s recent BB downgrade indicates Walgreens&#8217; leverage ratio could remain above five times into fiscal 2025 and beyond, Bloomberg added.
Price Action: WBA shares are trading higher by 2.24% to $11.41 at last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: refrina/Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/23/12/36213117/privacy-risks-flagged-major-pharmacy-chains-share-customer-data-with-authorities-without-warrant" target="_blank" rel="noreferrer noopener">Privacy Risks Flagged: Major Pharmacy Chains Share Customer Data With Authorities Without Warrant</a>.</li>
</ul>

Equities

Media

RADCQ

Walgreens Mulls Bond Sale As JPMorgan Gauges Investor Appetite: Report

TD Cowen analyst Robert Moskow downgrades Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) from Buy to Hold and lowers the price target from $105 to $61.

Downgrades

Price Target

Analyst Ratings

TD Cowen Downgrades Lamb Weston Hldgs to Hold, Lowers Price Target to $61

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) shares are trading higher by 1.41% to $43.55 during Thursday&#8217;s session. The stock was initially down then reversed in reaction to American Airlines Group Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and Southwest Airlines Co&#8217;s <a href="https://www.benzinga.com/news/earnings/24/07/39957077/southwest-airlines-q2-earnings-plummet-ceo-promises-transformational-changes">financial results</a>.
Delta is additionally facing financial setbacks due to a recent system failure causing thousands of flight cancellations and a <a href="https://www.benzinga.com/government/24/07/39936988/delta-air-lines-faces-500m-financial-hit-as-it-outage-causes-thousands-of-cancellations">federal investigation</a>. Citigroup cut its third-quarter earnings estimate for Delta by 60 cents per share to $1.37. Analysts estimate a $350 million impact on operating profit and potential fines.
<h2 class="wp-block-heading">What Else?</h2>
When major airlines like American Airlines and Southwest Airlines report worse-than-expected results, it signals broader industry challenges. Investors may assume that Delta, being part of the same industry, faces similar issues, such as increased operating costs, capacity management struggles, and demand fluctuations.
Southwest Airlines reported a significant 13% increase in operating expenses, driven by market-driven rate inflation in salaries, wages, benefits, and higher maintenance expenses. These cost pressures are likely affecting all airlines, including Delta, which may concern investors about Delta&#8217;s cost management and profitability.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39951461/markets-are-sounding-an-alarm-peter-schiff-warns-federal-reserve-should-cut-rates-b">Peter Schiff Warns Federal Reserve Should Cut Rates Before Recession Hits</a>

What's Going On With Delta Air Lines (DAL) Shares?

Media company Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) is proposing another presidential debate for <a href="https://www.benzinga.com/topic/2024-election">the 2024 election.</a>
The proposal comes after President Joe Biden has dropped out of the race and would allow voters to view two presidential debates between Donald Trump and Kamala Harris.
What Happened: Fox <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38111881/fox-is-the-winner-in-biden-trump-rematch-tv-stations-garner-bulk-of-political-ad-sp">could be a winner</a> in the 2024 election with viewers tuning in to Fox News for political commentary and interviews during the current political cycle. The media company also benefits from increased advertising spending during the election cycle.
A new proposal for a third 2024 presidential debate could also benefit Fox.
Fox News invited Kamala Harris and Donald Trump to appear at a presidential debate in Pennsylvania on Sept. 17, as reported by <a href="https://www.politico.com/news/2024/07/24/fox-news-debate-harris-trump-00170958">Politico</a>. Invitations were sent out to both candidates on Wednesday.
The debate would take place one week after a proposed second debate on Sept. 10. This debate was to be hosted by<a href="http://Trump Vs. Harris: 2024 Election Candidates Tied In New Poll, 65% Of Democrats Say Biden Stepping Down Increases Party's Chances Of Winning"> Walt Disney Co</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)-owned ABC News and originally scheduled to include Biden and Trump.
While it proposed Pennsylvania and the date of Sept. 17, Fox News is said to be open to discussions with the two campaign teams on the date, location and other items such as having a live audience. Robert F. Kennedy Jr. was not listed as an invite to the debate in the report.
Trump has committed to debating Harris in the past few days and had previously pushed for Fox News to host a debate.
Read Also: <a href="https://www.benzinga.com/general/politics/24/07/39946360/trump-vs-harris-2024-election-candidates-tied-in-new-poll-65-of-democrats-say-biden-stepping-dow">Trump Vs. Harris: 2024 Election Candidates Tied In New Poll, 65% Of Democrats Say Biden Stepping Down Increases Party&#8217;s Chances Of Winning</a>
Why It's Important: With less than four months to go before election day and the late departure of Biden in the race, debates between Harris and Trump could generate strong viewership.
The first 2024 presidential debate<a href="https://www.benzinga.com/general/politics/24/06/39563409/heres-how-many-people-watched-the-2024-presidential-debate-and-how-fox-beat-cnn-at-its-own-game"> was watched by over</a> 47 million viewers and set records for host CNN, which is a unit of Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>).
CNN hosted the debate, but also allowed networks to simulcast their live feed. This resulted in Fox News having the most viewers (8.82 million) for the debate and beating CNN (8.75 million), according to initial reports.
Fox also generated 3.48 million viewers on the FOX broadcast network and over 370,000 viewers on Fox Business.
The two 2020 presidential debates also saw Fox News lead the way in viewership. The two debates were not hosted by an individual network and broadcast widely by media networks.
Viewership for the first 2024 presidential debate was down from 73 million viewers and 84 million viewers for the 2020 and 2016 first presidential debates, respectively.
The debate between Harris and Trump could see increased viewership as they did not previously take each other on in a presidential debate and more undecided voters could want to hear more about Harris' policies going forward. &nbsp;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/07/39896462/the-simpsons-does-it-again-could-this-animated-show-veep-barbie-foreshadow-kamala-harris-wi">&#8216;The Simpsons&#8217; Does It Again? Could This Animated Show, &#8216;Veep,&#8217; &#8216;Barbie&#8217; Foreshadow Kamala Harris Winning 2024 Election</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

FOXA

Trump Vs. Harris: Fox News Proposes Another 2024 Presidential Debate, How Media Company Could Be Big Winner

Stephens &amp; Co. analyst Scott Fidel reiterates Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and maintains $320 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Molina Healthcare, Maintains $320 Price Target

Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) reported Wednesday second-quarter adjusted EPS of 70 cents, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 69 cents</a>.
The sales increased 7% (+8% on constant currency) to $1.632 billion, below the consensus of $1.653 billion.
The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1 billion, which grew 5%, or 6% on a <a href="https://www.benzinga.com/pressreleases/24/07/b39942479/edwards-lifesciences-reports-second-quarter-results" target="_blank" rel="noreferrer noopener">constant currency basis</a>.
Edwards&#8217; competitive position did not meaningfully change globally, although the company experienced some regional pressures, and pricing was maintained.
The company also agreed to acquire JenaValve Technology, a company focused on the transcatheter treatment of aortic regurgitation (AR).
Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR.
Building on an investment made in 2016, the company exercised its option to acquire Endotronix, a heart failure (HF) <a href="https://www.benzinga.com/pressreleases/24/07/b39942530/edwards-lifesciences-expands-structural-heart-portfolio-with-acquisitions-of-jenavalve-and-endotro" target="_blank" rel="noreferrer noopener">management solutions provider</a>.
Last month, Endotronix received FDA approval for Cordella, an implantable pulmonary artery pressure sensor allowing early, targeted therapeutic intervention. A CMS national coverage determination is expected in early 2025.
Edwards anticipates these investments will strengthen its leadership in structural heart offerings and represent long-term growth opportunities. Edwards expects minimal revenue contribution from these acquisitions in 2025.
The aggregate upfront purchase price is approximately $1.2 billion.
Guidance: Edwards Lifesciences anticipates second-half TAVR sales growth similar to the first-half year-over-year growth rate, or 5%-7% full-year growth versus previous guidance of 8 to 10%.
For Transcatheter Mitral and Tricuspid Therapies, the company increased 2024 sales guidance to the higher end of the previous $320 to $340 million range.
The company remains confident in full-year Surgical sales growth of 6 to 8%; it expects third-quarter sales of $1.56 billion-$1.64 billion versus a consensus of $1.65 billion.
The company expects EPS of $0.67-$0.71 versus a consensus of $0.69
William Blair notes that U.S. TAVR growth fell short of expectations, with mid-single-digit growth primarily due to hospital workflow pressures rather than competitive impacts. Recent approvals of mitral and tricuspid devices have constrained interventional procedure workflow in cath labs.
While a headwind for TAVR, analysts believe this is &#8220;validating the procedural demand within TMTT.&#8221;
William Blair maintains <a target="_blank" href="https://www.benzinga.com/quote/EW/analyst-ratings" rel="noreferrer noopener">an Outperform rating</a>.
The analyst adds, &#8220;While we acknowledge investor focus in the near term remains on TAVR growth, we continue to see the potential for rapid sales growth in this multi-billion dollar market that is low single-digits penetrated.&#8221;
Price Action: EW stock is down 28.7% at $62.11 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39956385/sanofi-raises-2024-profit-outlook-on-strong-q2-earnings-blockbuster-drug-dupixent-sees-strong-dem" target="_blank" rel="noreferrer noopener">Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand</a>.</li>
</ul>

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

Edwards Lifesciences Stock Tumbles, Highlights Slowdown In TAVR Business

An Australian judge has dismissed a <a href="https://www.benzinga.com/news/large-cap/24/01/36842117/weedkiller-woes-australian-court-nears-decision-in-bayers-roundup-trial">class action lawsuit</a> alleging that Bayer AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYZF#OTC">BAYZF</a>) Roundup weedkiller causes a type of blood cancer. This ruling is a significant victory for Bayer, facing numerous similar lawsuits in the United States.
Justice Michael Lee of Australia&#8217;s Federal Court ruled that the evidence was insufficient to link Roundup to non-Hodgkin&#8217;s lymphoma (NHL), a type of cancer that begins in the lymphatic system, part of the body&#8217;s germ-fighting immune system.
Related: <a target="_blank" href="https://www.benzinga.com/news/24/06/39185732/judge-slashes-bayers-massive-2b-roundup-verdict-to-400m" rel="noreferrer noopener">Judge Slashes Bayer&#8217;s Massive $2B Roundup Verdict To $400M</a>.
The decision supports Bayer&#8217;s stance that Roundup, a glyphosate-based herbicide, is safe.
Reuters highlights the company asserts it &#8220;fully stands behind its glyphosate-based products, which have been used around the world for almost 50 years.&#8221;
The Australian class action suit united more than 1,000 claimants, marking one of approximately 40 cases outside the United States, primarily in Canada and Australia.
The lead claimant, Kelvin McNickle, 41, allegedly used Roundup for over two decades before developing NHL at 35.
Bayer has won 14 of the last 20 Roundup trials in the United States. However, a series of losses in late 2023 and early 2024 resulted in over $4 billion in damages awarded to plaintiffs, significantly impacting investor confidence.
Despite this recent win, Bayer still faces over 50,000 outstanding claims in the United States. A U.S. court recently denied Bayer&#8217;s request for an agreement to prevent future cases.
To mitigate litigation risks, Bayer has replaced glyphosate with new active ingredients in its household products in the U.S. while continuing to sell glyphosate-based weedkillers to farmers, who heavily rely on it.
In May, Bayer&#8217;s Monsanto unit secured a significant victory. A Washington state appeals court overturned a $185 million verdict against the company over chemical contamination at a <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/38593423/bayers-monsanto-scores-legal-victory-as-185m-verdict-overturned" rel="noreferrer noopener">Seattle-area school</a>.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39958623/astrazeneca-posts-mixed-q2-earnings-still-raises-annual-guidance-on-strong-demand-for-cancer-rare" target="_blank" rel="noreferrer noopener">AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines</a>.</li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Legal

BAYRY

BAYZF

Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer

Shares of Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) are volatile Thursday following a court ruling allowing the ride-share companies to treat drivers as contractors.
What Happened: The California Supreme Court ruled that Proposition 22, a 2020 ballot measure, is constitutional. This measure allows ride-hailing companies like Uber and Lyft to classify their drivers as independent contractors rather than employees<a href="https://www.wsj.com/business/uber-and-lyft-win-california-judgment-to-treat-drivers-as-contractors-e274cddf">.</a>
This decision is a crucial win for gig-economy companies, preserving their business model and avoiding the additional costs associated with classifying drivers as employees.
UBER, LYFT Price Action: Uber shares were up by 1.62% at $67.21 and LYFT shares were down by 1.86% at $12.15 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image Via Shutterstock.

LYFT

UBER

Uber And LYFT Shares Are Volatile Today: What You Need To Know

U.S. Justice Dept Says U.S. Sues National General Holdings Corp And Subsidiaries For Falsely Placing Insurance On Hundreds Of Thousands Of Borrowers' Vehicles

Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares are trading higher today. The company reportedly inked a deal with Rai Way to implement its AI systems at the Italian firm&#8217;s data centers.
Oracle&#8217;s corporate clients will access its database, cloud, and disaster recovery solutions through Rai Way&#8217;s remote data centers, reported Reuters.
The companies noted that Rai Way&#8217;s remote data centers enhance cybersecurity by adding &#8220;a further layer of protection against any attempts by cyber-criminals to locate data geographically.&#8221;
Apart from this, Oracle inked a managed services agreement with a Saudi telecom operator Salam to support<a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39955486/salam-taps-oracle-to-optimize-business-operations-and-innovate-with-new-service-offerings" rel="noreferrer noopener"> ongoing digital transformation</a>.
Using an Information and Communication Technology-focused approach, Oracle will help Salam boost operational efficiency, proactively address potential issues, and ensure seamless service delivery to customers.
Ahmed Al-Anqari, CEO of Salam, said, &#8220;As a Saudi-born company, Salam is at a digital transformation milestone in its journey. Our focus is on contributing to the advancement of KSA&#8217;s ICT sector by enhancing our managed services among many other strategic initiatives.&#8221;
This month, Oracle unveiled Exadata Exascale, a cloud-based data architecture enhancing performance&nbsp;for <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39746996/whats-going-on-with-oracle-stock-on-friday" rel="noreferrer noopener">Oracle Database workloads</a>.
ORCL stock has gained around&nbsp;19%&nbsp;in the last 12 months. Investors can gain exposure to the stock via&nbsp;Pacer Funds Pacer Data And Digital Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRFK#NYSE">TRFK</a>) and&nbsp;IShares Expanded Tech-Software Sector ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>).
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39317779/oracles-strategic-pivot-to-ai-and-cloud-computing-yields-market-cap-surge-report" rel="noreferrer noopener">Oracle&#8217;s Strategic Pivot To AI And Cloud Computing Yields Market Cap Surge: Report</a>
Price Action: ORCL shares are up 0.73% at $139.78 at the last check on Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Contracts

ORCL

TRFK

What's Going On With Oracle Stock Thursday?

Stephens &amp; Co. analyst Scott Fidel reiterates Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Equal-Weight and maintains $200 price target.

Stephens & Co. Reiterates Equal-Weight on Universal Health Servs, Maintains $200 Price Target

Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) has outperformed the market over the past 20 years by 1.49% on an annualized basis producing an average annual return of 9.79%. Currently, Starbucks has a market capitalization of $84.08 billion. 
Buying $1000 In SBUX: If an investor had bought $1000 of SBUX stock 20 years ago, it would be worth $6,389.49 today based on a price of $74.23 for SBUX at the time of writing.
<h3>Starbucks's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721932263_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Aeris Resources

News

Latest news for Aeris Resources (OTC:ARSRF) Stock